What is it about?
Fenofibrate reduced the incidence of heart failure events in people with type 2 diabetes treated with a standard glucose-lowering therapy.
Featured Image
Read the Original
This page is a summary of: Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD, Diabetes Care, March 2022, American Diabetes Association,
DOI: 10.2337/dc21-1977.
You can read the full text:
Contributors
The following have contributed to this page
